The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CID3032648     trisodium; oxo-oxostibanyloxy-stibane; (2R...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Solustibosan


High impact information on Solustibosan


Chemical compound and disease context of Solustibosan


Biological context of Solustibosan


Anatomical context of Solustibosan


Associations of Solustibosan with other chemical compounds


Gene context of Solustibosan


Analytical, diagnostic and therapeutic context of Solustibosan


  1. Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. Anabwani, G.M., Ngira, J.A., Dimiti, G., Bryceson, A.D. Lancet (1983) [Pubmed]
  2. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Hepburn, N.C., Siddique, I., Howie, A.F., Beckett, G.J., Hayes, P.C. Lancet (1993) [Pubmed]
  3. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Ballou, W.R., McClain, J.B., Gordon, D.M., Shanks, G.D., Andujar, J., Berman, J.D., Chulay, J.D. Lancet (1987) [Pubmed]
  4. Renal clearance of pentavalent antimony (sodium stibogluconate). Rees, P.H., Keating, M.I., Kager, P.A., Hockmeyer, W.T. Lancet (1980) [Pubmed]
  5. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. Murray, H.W., Oca, M.J., Granger, A.M., Schreiber, R.D. J. Clin. Invest. (1989) [Pubmed]
  6. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Mishra, M., Biswas, U.K., Jha, A.M., Khan, A.B. Lancet (1994) [Pubmed]
  7. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages. Fan, K., Zhou, M., Pathak, M.K., Lindner, D.J., Altuntas, C.Z., Tuohy, V.K., Borden, E.C., Yi, T. J. Immunol. (2005) [Pubmed]
  8. Anticancer activity of sodium stibogluconate in synergy with IFNs. Yi, T., Pathak, M.K., Lindner, D.J., Ketterer, M.E., Farver, C., Borden, E.C. J. Immunol. (2002) [Pubmed]
  9. Sodium stibogluconate (Pentostam) overdose during treatment of American cutaneous leishmaniasis. Herwaldt, B.L., Kaye, E.T., Lepore, T.J., Berman, J.D., Baden, H.P. J. Infect. Dis. (1992) [Pubmed]
  10. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Sereno, D., Lemesre, J.L. Antimicrob. Agents Chemother. (1997) [Pubmed]
  11. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. Mueller, M., Balasegaram, M., Koummuki, Y., Ritmeijer, K., Santana, M.R., Davidson, R. J. Antimicrob. Chemother. (2006) [Pubmed]
  12. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Llanos-Cuentas, A., Echevarría, J., Cruz, M., La Rosa, A., Campos, P., Campos, M., Franke, E., Berman, J., Modabber, F., Marr, J. Clin. Infect. Dis. (1997) [Pubmed]
  13. Out-patient parenteral antimicrobial therapy--a viable option for the management of cutaneous leishmaniasis. Seaton, R.A., Morrison, J., Man, I., Watson, J., Nathwani, D. QJM : monthly journal of the Association of Physicians. (1999) [Pubmed]
  14. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Nieto, J., Alvar, J., Mullen, A.B., Carter, K.C., Rodríguez, C., San Andrés, M.I., San Andrés, M.D., Baillie, A.J., González, F. Antimicrob. Agents Chemother. (2003) [Pubmed]
  15. Antileishmanial activity of sodium stibogluconate fractions. Roberts, W.L., Rainey, P.M. Antimicrob. Agents Chemother. (1993) [Pubmed]
  16. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? Yardley, V., Ortuno, N., Llanos-Cuentas, A., Chappuis, F., Doncker, S.D., Ramirez, L., Croft, S., Arevalo, J., Adaui, V., Bermudez, H., Decuypere, S., Dujardin, J.C. J. Infect. Dis. (2006) [Pubmed]
  17. HIV-1 Replication Is Stimulated by Sodium Stibogluconate, the Therapeutic Mainstay in the Treatment of Leishmaniasis. Barat, C., Zhao, C., Ouellette, M., Tremblay, M.J. J. Infect. Dis. (2007) [Pubmed]
  18. Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate. Haimeur, A., Ouellette, M. Antimicrob. Agents Chemother. (1998) [Pubmed]
  19. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species. Maes, L., Vanden Berghe, D., Germonprez, N., Quirijnen, L., Cos, P., De Kimpe, N., Van Puyvelde, L. Antimicrob. Agents Chemother. (2004) [Pubmed]
  20. The Indian langur: preliminary report of a new nonhuman primate host for visceral leishmaniasis. Anuradha, n.u.l.l., Pal, R., Zehra, K., Katiyar, J.C., Sethi, N., Bhatia, G., Singh, R.K. Bull. World Health Organ. (1992) [Pubmed]
  21. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. Baillie, A.J., Coombs, G.H., Dolan, T.F., Laurie, J. J. Pharm. Pharmacol. (1986) [Pubmed]
  22. Immunological studies of pancytopenia in visceral leishmaniasis. Pollack, S., Nagler, A., Liberman, D., Oren, I., Alroy, G., Katz, R., Schechter, Y. Isr. J. Med. Sci. (1988) [Pubmed]
  23. Effect of sodium stibogluconate on in vitro lymphocyte responses in Kenyan visceral leishmaniasis. Koech, D.K. East African medical journal. (1984) [Pubmed]
  24. The sensitivity of Leishmania species to aminosidine. Neal, R.A., Allen, S., McCoy, N., Olliaro, P., Croft, S.L. J. Antimicrob. Chemother. (1995) [Pubmed]
  25. Immunochemotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate). Bhakuni, V., Kulkarni, S., Ali, V., Singh, U.K., Levy, H.B., Maheshwari, R.K. J. Interferon Cytokine Res. (1999) [Pubmed]
  26. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation. Berhe, N., Ali, A., Hailu, A., Yeneneh, H. Acta Trop. (1994) [Pubmed]
  27. Leishmania donovani: An in vitro study of antimony-resistant amphotericin B-sensitive isolates. Sharief, A.H., Gasim Khalil, E.A., Theander, T.G., Kharazmi, A., Omer, S.A., Ibrahim, M.E. Exp. Parasitol. (2006) [Pubmed]
  28. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Alexander, J., Carter, K.C., Al-Fasi, N., Satoskar, A., Brombacher, F. Eur. J. Immunol. (2000) [Pubmed]
  29. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody. Nabors, G.S., Farrell, J.P. Am. J. Trop. Med. Hyg. (1995) [Pubmed]
  30. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate. Mullen, A.B., Lawrence, C.E., McFarlane, E., Wei, X.Q., Carter, K.C. Immunology (2006) [Pubmed]
  31. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. Pathak, M.K., Yi, T. J. Immunol. (2001) [Pubmed]
  32. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. Murray, H.W., Berman, J.D., Wright, S.D. J. Infect. Dis. (1988) [Pubmed]
  33. Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. al Jaser, M., el-Yazigi, A., Kojan, M., Croft, S.L. Antimicrob. Agents Chemother. (1995) [Pubmed]
  34. Intralesional injection of sodium stibogluconate by dermal pressure-jet instrument. Kellum, R.E. J. Am. Acad. Dermatol. (1987) [Pubmed]
  35. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Chulay, J.D., Spencer, H.C., Mugambi, M. Am. J. Trop. Med. Hyg. (1985) [Pubmed]
  36. New World cutaneous leishmaniasis in returned travellers: treatment failures using intravenous sodium stibogluconate. Lawn, S.D., Yardley, V., Vega-Lopez, F., Watson, J., Lockwood, D.N. Trans. R. Soc. Trop. Med. Hyg. (2003) [Pubmed]
WikiGenes - Universities